Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy： A pilot study

• Published in: World journal of gastroenterology : WJG 2007-12, Vol.13 (46), p.6231-6235
• Main Authors: Kwon, Hyuk-Chan, Oh, Sung Yong, Lee, Suee, Kim, Sung-Hyun, Kim, Hyo-Jin
• Format: Article
• Language: English
• Subjects: 5-氟脲嘧啶; Adenocarcinoma - blood supply; Adenocarcinoma - drug therapy; Adenocarcinoma - metabolism; Adult; Aged; Angiogenesis Inhibitors - adverse effects; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal - adverse effects; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab; Camptothecin - administration & dosage; Camptothecin - adverse effects; Camptothecin - analogs & derivatives; Camptothecin - therapeutic use; Colorectal Neoplasms - blood supply; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - metabolism; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil - administration & dosage; Fluorouracil - adverse effects; Humans; Irinotecan; Leucovorin - administration & dosage; Leucovorin - adverse effects; Male; Middle Aged; Neovascularization, Pathologic - drug therapy; Organoplatinum Compounds - adverse effects; Organoplatinum Compounds - therapeutic use; Oxaliplatin; Pilot Projects; Thrombospondins - metabolism; Vascular Endothelial Growth Factor A - metabolism; 治疗药物; 甲酰四氢叶酸; 结肠直肠癌
• ISSN: 1007-9327; 2219-2840
• DOI: 10.3748/wjg.13.6231

AIM： To evaluate the combination of bevacizumab with infusional 5-fluorouracil （5-FU）, leucovorin （LV） and irinotecan （FOLFIRI） in patients with advanced colorectal cancer （CRC） pretreated with combination regimens including irinotecan and oxaliplatin. METHODS： Fourteen patients （median age 56 years） with advanced CRC, all having progressed after oxaliplatin- and irinotecan-based combination chemotherapy, were enrolled in this study. Patients were treated with 2 h infusion of irinotecan 150 mg/m2 on d 1, plus bevacizumab 5 mg/kg iv infusion for 90 min on d 2, and iv injection of LV 20 mg/m2 followed by a bolus of 5-FU 400 mg/m2 and then 22 h continuous infusion of 600 mg/m2 given on two consecutive days every 14 d. RESULTS： The median number of cycles of chemotherapy was six （range 3-12）. The response rate was 28.5%, one patient had a complete response, and three patients had a partial response. Eight patients had stable disease. The median time to progression was 3.9 mo （95% CI 2.0-8.7）, and the median overall survival was 10.9 mo （95% CI 9.6-12.1）. Grade 3/4 neutropenia occurred in five patients, and two of these developed neutropenic fever. Grade 3 hematuria and hematochezia occurred in one. Grade 2 proteinuria occurred in two patients. However, hypertension, bowel perforation or thromboembolic events did not occur in a total of 90 cycles. CONCLUSION： Bevacizumab with FOLFIRI is well tolerated and a feasible treatment in patients with heavily treated advanced CRC.